Rapastinel

• Description :

  Rapastinel (GLYX-13) is an N-methyl-D-aspartate receptor (NMDAR) modulator with partial agonist properties.

• Product Name Alternative :

  GLYX-13

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  IGluR

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/Rapastinel.html

• Purity :

  99.78

• Solubility :

  DMSO : ≥ 32 mg/mL

• Smiles :

  O=C(N(CCC1)[C@@H]1C(N[C@H](C(N)=O)[C@H](O)C)=O)[C@H](CCC2)N2C([C@@H](N)[C@H](O)C)=O

• Molecular Formula :

  C18H31N5O6

• Molecular Weight :

  413.47

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Burgdorf J, et al. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience. 2015 Nov 12;308:202-11.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• Isoform :

  NMDA Receptor

• CAS Number :

  [117928-94-6]